ALOPESIA AREATA SEBAGAI SEKUELE POST REINFEKSI COVID-19
DOI:
https://doi.org/10.33820/mdvi.v49i3.344Keywords:
alopesia areata, covid-19, reinfeksiAbstract
ABSTRACT
Introduction: Coronavirus disease (COVID-19) is a global pandemic that caused unprecedented morbidity and mortality. Aside from respiratory symptoms, dermatological manifestations have been widely reported, with the predominant manifestation was the hair loss. Case report: A 32-year-old male resident doctor experienced a solitary patchy alopecia areata (AA) on vertex, started 1 month after being reinfected by SARS-CoV-2. Personal history was negative for autoimmune and trichological disorders, no family history with AA. Trichoscopy examination revealed yellow dots, black dots, broken hairs, and exclamation-mark hairs. Treated with topical minoxidil and tretinoin for three months with excellent response. Discussion: The SARS-CoV-2 infection and related anxiety or emotional stress due to two times COVID-19 infections could have triggered AA. SARS-CoV-2 infection induces an activation of cytokine cascade involving interferon to disrupt hair follicle immune privilege (HFIP). Meanwhile, psychological stress enhances neurogenic inflammations and induces a shift to the immune response to type 1 T-helper cells and increases apoptosis of epithelial cells that affects hair growth. There were three prior reports about new onset AA in post COVID-19. Our report is the fourth case of new onset AA in post COVID-19, but the only case with COVID-19 reinfection. Conclusion: Our report on new onset AA in post COVID-19 reinfection provides an insight into the possible association between SARS-CoV-2 infection and AA. The onset of AA in COVID-19 patient represents a sequelae of post COVID-19 caused by immune responses or psychological distress, and there appears to be a close association in timing between them.
Downloads
References
2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020 May 1;20(5):533–4.
3. Nalbandian A, Sehgal K, Gupta A, Madhavan M V., McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021 Apr 1;27(4):601–15.
4. Wollina U, KaradaÄŸ AS, Rowland-Payne C, Chiriac A, Lotti T. Cutaneous signs in COVID-19 patients: A review. Dermatol Ther. 2020 Sep 1;33(5).
5. Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C, Desai SR, et al. The spectrum of COVID-19–associated dermatologic manifestations: An international registry of 716 patients from 31 countries. J Am Acad Dermatol. 2020 Oct 1;83(4):1118–29.
6. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
7. Garrigues E, Janvier P, Kherabi Y, Le Bot A, Hamon A, Gouze H, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020 Dec 1;81(6):e4–6.
8. Lee J, Yousaf A, Fang W, Kolodney MS. Male balding is a major risk factor for severe COVID-19. J Am Acad Dermatol. 2020 Nov 1;83(5):e353–4.
9. Rizzetto G, Diotallevi F, Campanati A, Radi G, Bianchelli T, Molinelli E, et al. Telogen effluvium related to post severe Sars-Cov-2 infection: Clinical aspects and our management experience. Dermatol Ther. 2021 Jan 1;34(1).
10. Trüeb RM, Dias MFRG. Alopecia Areata: a Comprehensive Review of Pathogenesis and Management. Clin Rev Allergy Immunol. 2018 Feb 1;54(1):68–87.
11. Rinaldi F, Trink A, Giammaria G, Pinto D. Italian Survey for the Evaluation of the Effects of Coronavirus Disease 2019 (COVID-19) Pandemic on Alopecia Areata Recurrence. Dermatol Ther (Heidelb). 2021;11:339–45.
12. Kutlu Ö, Aktaş H, İmren IG, Metin A. Short-term stress-related increasing cases of alopecia areata during the COVID-19 pandemic. J Dermatolog Treat. 2022;33(2):1177.
13. Turkmen D, Altunisik N, Sener S, Colak C. Evaluation of the effects of COVID-19 pandemic on hair diseases through a web-based questionnaire. Dermatol Ther. 2020 Nov 1;33(6):e13923.
14. Flevenson D. COVID-19: association with rapidly progressive forms of alopecia areata. Int J Dermatol. 2021;60(1):127.
15. Sgubbi P, Savoia F, Calderoni O, Longo R, Stinchi C, Tabanelli M. Alopecia areata in a patient with SARS-Cov-2 infection. Dermatol Ther. 2020 Nov 1;33(6):e14295.
16. Rossi A, Magri F, Michelini S, Sernicola A, Muscianese M, Caro G, et al. New onset of alopecia areata in a patient with SARS-CoV-2 infection: Possible pathogenetic correlations? J Cosmet Dermatol. 2021 Jul 1;20(7):2004–5.
17. Richardson CT, Hayden MS, Gilmore ES, Poligone B. Evaluation of the Relationship between Alopecia Areata and Viral Antigen Exposure. Am J Clin Dermatol. 2018 Feb 1;19(1):119–26.
18. Peters EMJ, Müller Y, Snaga W, Fliege H, Reißhauer A, Schmidt-Rose T, et al. Hair and stress: A pilot study of hair and cytokine balance alteration in healthy young women under major exam stress. PLoS One. 2017 Apr 1;12(4).
19. Dixit R, Qureshi D, Mathur S. Alopecia caused by isoniazid. J Pharmacol Pharmacother. 2014;5(2):155–7.
20. Seung Shin H, Hyun Won C, Ho Lee S, Sang Kwon O, Han Kim K, Chul Eun H. Efficacy of 5% Minoxidil versus Combined 5% Minoxidil and 0.01% Tretinoin for Male Pattern Hair Loss A Randomized, Double-Blind, Comparative Clinical Trial. Am J Clin Dermatol. 2007;8(5):285–90.
